# A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Study · id `cardio:ct-nct04706637` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04706637](<https://clinicaltrials.gov/study/NCT04706637>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04706637

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04706637. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04706637, source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)
- Planned start: 2021-02-01 (anticipated) (ClinicalTrials.gov record NCT04706637, source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)
- Primary completion: 2022-01-31 (anticipated) (ClinicalTrials.gov record NCT04706637, source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)
- Completion: 2023-01-31 (anticipated) (ClinicalTrials.gov record NCT04706637, source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04706637, source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04706637-2021-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
- Acronym: EVOMETA
- Condition: Bone Diseases, Metabolic
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Evogliptin
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Kyung Hee University Hospital at Gangdong
- Lead sponsor class: OTHER
- Collaborator: Dong-A ST Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Kyung Hee University Hospital at Gangdong (`cardio:org-kyung-hee-university-hospital-at-gangdong`)
- Registry lists this organization as a collaborator: Dong-A ST Co., Ltd. (`cardio:org-dong-a-st-co-ltd`)

## Provenance

Content hash: 5592811afc2f72ddc3a66c1f0974bed5608576f3cc5fdcf2a67982b43c95a263
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
